Multigenerational health histories strong medicine for preventive health

Broadening clinician access to the health histories of patients’ parents and grandparents would help ward off or better treat numerous chronic illnesses common to middle-aged adults in the U.S.

So suggests a study conducted at Duke University and the University of North Carolina at Chapel Hill and published July 3 in the American Journal of Preventive Medicine.

Naomi Duke, MD, PhD, MPH, Kathleen Mullan Harris, PhD, and colleagues began with data on 12,300 participants whose health was followed in a national longitudinal study as they aged from adolescence to adulthood.

With this data they merged health histories submitted by more than 2,000 participants’ parents who took part in a parallel project by reporting parents’ and grandparents’ health as well as their own.  

The team found participants’ health histories strongly correlated with those of three generations of forebears on cardiovascular disease and various other chronic conditions, with apparent ramifications for care improvement going forward.

“Multigenerational health histories have value for quantifying the probability of diabetes, obesity, depression and hyperlipidemia in early mid-adulthood,” Duke et al. comment. “Family health history knowledge is relevant for health promotion and disease prevention strategies.”

Study posted here (behind paywall).

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.